|Awarded On||November 19, 2015|
|Title||Development of Therapeutics Targeting Truncated Adenomatous Polyposis Coli (APC) as a Novel Prevention and Intervention Strategy for Colorectal Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Jerry W Shay|
Despite the enormous burdens placed on the U.S. healthcare system, treatments for colorectal cancer (CRC) is primarily reliant upon chemotherapeutic agents that act with minimal specificity for the underlying genetic basis of disease. The adenomatous polyposis coli (APC) gene is specifically altered in ~80% of colon tumors. We have developed a small molecule targeted therapy for the vast majority of CRC patients expressing truncated APC proteins. We have conducted a high-throughput 200,000 small molecule screen and identified a lead compound that shows selective toxicity to human CRC cells expressing a truncated APC protein but not normal human colonic epithelial cells. This lead compound ...